LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

Search

Bluebird Bio Inc

Cerrado

4.9 -1.41

Resumen

Variación precio

24h

Actual

Mínimo

4.9

Máximo

4.97

Bluebird Bio Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Comparación entre iguales

Cambio de precio

Bluebird Bio Inc Esperado

Acerca de Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.